Melanotan 2 (MT-II) is one of the most intriguing research peptides, and it is being evaluated for its potential action in various research avenues. Clinical
Seven abstracts emphasize Jazz's commitment to advancing the care and understanding of debilitating sleep disorders such as narcolepsy and idiopathic hypersomnia DUBLIN, May 31, 2023 /PRNewswire/
/PRNewswire/ Nuance Pharma ("the Company") announces the Center for Drug Evaluation ("CDE") has approved its Investigational New Drug ("IND") application.
An update on the emerging evidence of the effects and safety of disease modifying therapies for the management of children with spinal muscular atrophy (SMA).